Vaccines and animal models for arboviral encephalitides.
Arthropod-borne viruses ("arboviruses") cause significant human illness ranging from mild, asymptomatic infection to fatal encephalitis or hemorrhagic fever. The most significant arboviruses causing human illness belong to genera in three viral families, Togaviridae, Flaviviridae, and Bunyaviridae. These viruses represent a significant public health threat to many parts of the world, and, as evidenced by the recent introduction of the West Nile virus (WNV) to the Western Hemisphere, they can no longer be considered specific to any one country or region of the world. Like most viral diseases, there are no specific therapies for the arboviral encephalitides; therefore, effective vaccines remain the front line of defense for these diseases. With this in mind, the development of new, more effective vaccines and the appropriate animal models in which to test them become paramount. In fact, for many important arboviruses (e.g. California serogroup and St. Louis encephalitis viruses), there are currently no approved vaccines available for human use. For others, such as the alphaviruses, human vaccines are available only as Investigational New Drugs, and thus are not in widespread use. On the other hand, safe and effective vaccines against tick-borne encephalitis virus (TBEV) and Japanese encephalitis virus (JEV) have been in use for decades. New challenges in vaccine development have been met with new technologies in vaccine research. Many of the newer vaccines are now being developed by recombinant DNA technology. For example, chimeric virus vaccines have been developed using infectious clone technology for many of the arboviruses including, WNV, JEV, and TBEV. Other successful approaches have involved the use of naked DNA encoding and subsequently expressing the desired protective epitopes. Naked DNA vaccines have been used for TBEV and JEV and are currently under development for use against WNV. The development of less expensive, more authentic animal models to evaluate new vaccines against arboviral diseases will become increasingly important as these new approaches in vaccine research are realized. This article reviews the current status of vaccines, both approved for use and those in developmental stages, against the major arboviral encephalitides causing human disease. In addition, research on animal models, both past and present, for these diseases are discussed.
Nalca
Aysegul
A
Homeland Security and Infectious Disease Research Division, Southern Research Institute, 431 Aviation Way, Frederick, MD 21701, USA. nalca@sri.org
Fellows
Patricia F
PF
Whitehouse
Chris A
CA
D000818:Animals; D001103:Arboviruses / Q000472:pathogenicity; D002043:Bunyaviridae / Q000472:pathogenicity; D004195:Disease Models, Animal; D004668:Encephalitis Viruses / Q000276:immunology / Q000472:pathogenicity / Q000502:physiology / Q000648:ultrastructure; D004671:Encephalitis, Arbovirus / Q000517:prevention & control*; D018067:Flaviviridae / Q000472:pathogenicity; D006801:Humans; D014035:Togaviridae / Q000472:pathogenicity; D014614:Vaccines, Synthetic; D014765:Viral Vaccines
D014614:Vaccines, Synthetic; D014765:Viral Vaccines